Status:
RECRUITING
Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis
Lead Sponsor:
AstraZeneca
Conditions:
Myasthenia Gravis, Generalized
Eligibility:
All Genders
18+ years
Brief Summary
The Polish multicentre observational (non-interventional) study aiming to collect data on the management and clinical outcomes of patients with gMG that received ravulizumab.
Detailed Description
The Polish, prospective, multicenter, observational, cohort study designed to collect longitudinal data on the management and clinical outcomes of patients with gMG naive to complement inhibitors who ...
Eligibility Criteria
Inclusion
- Adult (aged ≥18 years) patients with gMG, naive to complement inhibitors, receiving ravulizumab treatment in the frames of NDP in Poland.
- Patients willing to participate in the study and signed Informed Consent Form (ICF).
- Vaccination against N. meningitidis
Exclusion
- Those who plan to participate in gMG clinical trial on/after the date of first ravulizumab infusion through NDP.
- Cognitive incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.
Key Trial Info
Start Date :
May 15 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2029
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06909253
Start Date
May 15 2025
End Date
December 31 2029
Last Update
December 19 2025
Active Locations (15)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Bydgoszcz, Poland
2
Research Site
Bydgoszcz, Poland
3
Research Site
Gdansk, Poland
4
Research Site
Katowice, Poland